TB Alliance announces the appointment of David Greeley as Senior Vice President, External Affairs. Mr. Greeley will be responsible for TB Alliance's resource mobilization, policy, advocacy, and community engagement initiatives and for augmenting support for the organization's promising pipeline of potential new TB drug regimens. David will be a member of the TB Alliance's senior management team.
David comes to the TB Alliance with more than 25 years of experience working for various international nonprofit development organizations and also for the pharmaceutical company Merck & Co., Inc. Most recently, David was Vice President, Center for Private Sector Health Initiatives, at FHI 360, a nonprofit dedicated to improving the health and well-being of vulnerable populations. There, he was responsible for facilitating partnerships between the public, nonprofit, and private sectors to provide health information, services, and products to underserved communities in the developing world. He raised more than $100 million in contracts and oversaw a staff of 75 professionals operating in nine countries. At Merck, David was the Senior Director of the company's Global HIV/AIDS programs in the Office of Corporate Responsibility, overseeing the company's access programs, public/private partnerships, policy, and stakeholder relations. From 1998-2007, he served as Merck's Senior Director of Public Affairs and Policy for the Latin America and Caribbean region.
"TB Alliance needs to scale up efforts to ensure the resources are available to support the advancement of TB cures to the people that need them," said Mel Spigelman, President and CEO, TB Alliance. "David Greeley will play a pivotal role in ensuring a sustainable stream of revenue and partnerships that will help us prepare for the advancement and introduction of new TB treatments."
Earlier in his career, David worked in roles of increasing responsibilities at the nonprofit organizations Population Services International (PSI) and CARE and has worked and lived in the US, Latin America, Asia, and Africa. He also served as a Peace Corps Volunteer in West Africa in the early 1980s.
"Over the past decade, the TB Alliance has emerged as a source of hope for the millions around the world suffering from TB. To deliver on the promise of the pipeline will require continued and expanded support from donors, policy makers, communities, and a host of other stakeholders," said David Greeley. "I'm excited and eager to invest my skills and energy in support of the TB Alliance's mission."
Every year, 1.4 million people worldwide die from TB. It is estimated that the bacillus that causes TB infects one-third of the world's population and the threat of drug resistance is growing. New, faster-acting, simpler drug regimens are critical to defeating this ancient disease.
Director of Communications, TB Alliance